Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial
to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with
osteoporosis at high risk of fracture
Phase:
Phase 3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Calcium Calcium, Dietary Ergocalciferols Vitamin D Vitamins